7 recruiting, 4 not yet recruiting, 1 active not recruiting. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 7, Not yet recruiting 4, Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neoadjuvant Chemoimmunotherapy: new trials by email Literature Review of Neoadjuvant Chemoimmunotherapy trials Research Report on Neoadjuvant Chemoimmunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response lattice radiation therapy - Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-07-01 | 2026-06-26 |
| Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study Iparomlimab/Tuvonralimab, Capecitabine, Oxaliplatin - Colon Cancer (Stage II &Amp; III), Immunotherapy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 45 | 2026-04-20 | 2026-04-24 |
| Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel - Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2025-09-20 | 2025-08-28 |
| Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy - Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 70 | 2025-08-15 | 2025-08-22 |
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability - Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura | Phase 1 / Phase 2 | Recruiting | University Hospital, Antwerp | 37 | 2025-07-22 | 2025-08-13 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 50 | 2024-09-03 | 2024-09-19 |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-05-08 | 2024-11-05 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Guo Xufeng | 73 | 2023-09-07 | 2023-09-28 |
| Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma Sintilimab combined with XELOX - Pathological Complete Response, Rectal Cancer | Phase 2 | Active not recruiting | The First Affiliated Hospital of Anhui Medical University | 50 | 2022-06-01 | 2025-11-21 |
Uterine Cervical Neoplasms (4) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Mesothelioma, Malignant (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (10) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Uterine Cervical Diseases (4) · Uterine Diseases (4)
Cisplatin (5) · camrelizumab (3) · Oxaliplatin (2) · Taxes (2) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Brachytherapy (1) · Capecitabine (1) · Carboplatin (1) · Cerebral Decortication (1) · Conization (1) · Propranolol (1) · Radiotherapy (1) · Surgical Procedures, Operative (1) · Tegafur (1)
Tongji Hospital (4) · Sun Yat-sen University (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Guo Xufeng (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The First Affiliated Hospital of Anhui Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Hospital, Antwerp (1)
China (9) · Belgium (1)
Ding Ma (4) · Bin Wang (1) · Changqing Pan (1) · Yujie Liang (1)
PMID 15825201, PMID 18486742, PMID 18784101, PMID 23129742, PMID 24419108, PMID 27718784, PMID 30509740, PMID 31679945, PMID 33243985, PMID 34160577, PMID 34473219, PMID 35585121, PMID 35766967, PMID 37395170, PMID 37991778, PMID 38110599, PMID 38467604, PMID 41582028, PMID 42172490
2023 (1)